Cosibelimab-ipdl (Unloxcyt) — CPB 1074 | AETNA Coverage Update

Aetna modified CPB 1074 for cosibelimab-ipdl (Unloxcyt), effective December 20, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its Unloxcyt coverage policy under CPB 1074 Aetna system, covering the PD-L1 inhibitor cosibelimab-ipdl for cutaneous squamous cell carcinoma (CSCC). The primary billing code is J9275 (injection, cosibelimab-ipdl, 2 mg), administered via infusion and billed with CPT 96413 and 96415. If your oncology or dermatology practice treats advanced CSCC patients on Aetna commercial plans, this policy update sets the rules for reimbursement starting December 20, 2025.

Quick-Reference Table

Aetna Cosibelimab-ipdl Coverage Criteria and Medical Necessity Requirements 2025

The Aetna cosibelimab-ipdl coverage policy covers exactly one FDA-approved indication: metastatic or locally advanced cutaneous squamous cell carcinoma. That narrow scope matters. If you're billing J9275 for anything else, Aetna will deny it as experimental or investigational — no exceptions in this policy.

The medical necessity standard is specific. The member must have metastatic or locally advanced CSCC and must not be a candidate for curative surgery or curative radiation. Both conditions apply. A patient who could pursue surgery but chooses not to does not meet criteria.

Precertification is mandatory for all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax (888) 267-3277 before administering the first dose. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal.

The site of care also matters. Aetna's Site of Care Utilization Management Policy applies to cosibelimab-ipdl infusions. Before assuming the hospital outpatient department is the right setting, check Aetna's drug infusion site-of-care policy for your patient's plan. A denial based on site of service is a recoverable problem — but only if you catch it before the claim goes out.

Prior authorization requirements apply to every infusion. There is no first-dose exception. If your team treats the prior auth as something to handle after the first administration, expect a claim denial.

Aetna Cosibelimab-ipdl Exclusions and Non-Covered Indications

This policy has one hard exclusion, and it's clinically significant: members who have experienced disease progression while on a PD-1 or PD-L1 inhibitor therapy are not eligible for Unloxcyt coverage.

Cosibelimab-ipdl is itself a PD-L1 inhibitor. So if your patient progressed on cemiplimab, pembrolizumab, nivolumab, or any other checkpoint inhibitor in this class, Aetna will not cover Unloxcyt. Full stop.

This is the exclusion most likely to generate a claim denial in the real world. At the time of prior auth, your clinical team needs to document the patient's treatment history clearly. If the oncologist's notes show prior PD-1 or PD-L1 exposure without documenting the response or lack of progression, the prior auth reviewer may default to a denial.

Beyond the PD-1/PD-L1 exclusion, Aetna treats all off-label uses as experimental, investigational, or unproven. Unloxcyt for any indication outside metastatic or locally advanced CSCC will not be covered under this policy. That includes any use in head and neck squamous cell carcinoma, lung cancer, or any other tumor type not listed.

Coverage Indications at a Glance

Aetna Cosibelimab-ipdl Billing Guidelines and Action Items 2025

The effective date of December 20, 2025 means these rules are live now. If your team is already treating CSCC patients with Unloxcyt under Aetna commercial plans, audit those accounts this week.

CPT, HCPCS, and ICD-10 Codes for Cosibelimab-ipdl Under CPB 1074

Covered HCPCS Codes (When Selection Criteria Are Met)

Related CPT Administration Codes

Key ICD-10-CM Diagnosis Codes